Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Single Annual EMA Fee Proposal Holds Most Promise For Pharma

Annual Fee Concept Can Simplify Many Of The Current Complexities

Executive Summary

Europe’s research-based industry association picks its preferred way forward for simplifying the European Medicines Agency’s fee system.

You may also be interested in...



Loud And Clear: EMA Gets Message On Advancing Reg Science

The European Medicines Agency has identified key areas where stakeholders want to see it deliver a real change over the next five years.

Keep It Simple: EU Consults On Future Design Of EMA’s Fee System

Following a report that identified several shortcomings of the European Medicines Agency fee system, the European Commission has suggested various options to make it sustainable and future-proof.

Roche’s Eye Drug Scores First UK Approval Under Access Consortium

The UK MHRA has approved its first drug under an international work-sharing initiative that also includes regulators from Australia, Canada, Singapore and Switzerland.

Topics

UsernamePublicRestriction

Register

PS141071

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel